Sumesh Kachroo, PhD

Janssen Scientific Affairs, LLC
Horsham, Pennsylvania

Disclosure information not submitted.

Presentation(s):

• D0372 - Evaluation of Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics With Three Years of Follow-Up

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET

• D0369 - Long-Term Persistence to Ustekinumab and Adalimumab Among Bio-Naïve Patients With Crohn's Disease

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET

• D0371 - Non-Biologic Medication Use Pre- and Post-Ustekinumab Initiation Among Patients With Ulcerative Colitis

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET

• D0370 - Persistence Among Patients With Crohn’s Disease Previously Treated With an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET

• D0373 - Relationship Between Hospitalization, Surgery and Achievement of Clinical Remission or Clinical Response in Moderate to Severe Crohn’s Disease Patients: Results From the UNITI/IM-UNITI Trials

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET